Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Projected Market Size and Growth Rates for the Chronic Pancreatitis (CP) Market From 2025 To 2029?
The market size for chronic pancreatitis (cp) has significantly expanded in the past few years and is projected to increase from $4.91 billion in 2024 to $5.23 billion in 2025. This growth is expected to maintain a compound annual growth rate (CAGR) of 6.4%. Factors such as growing alcohol intake, escalating instances of smoking, genetic susceptibilities and family histories, growing consciousness about pancreatic conditions, rising diabetes incidences related to pancreatitis, enhanced healthcare expenditure, as well as better access to healthcare services, are responsible for the growth experienced in the previous period.
The market for chronic pancreatitis (cp) is set to experience robust expansion in the following years, with projections suggesting it will reach$6.66 billion by 2029, increasing at a compound annual growth rate (CAGR) of 6.2%. The accelerated growth projected during the forecast period can be linked to various factors including an aging population, increased need for enzyme replacement therapies, heightened consciousness of early diagnosis, healthcare infrastructure development in emerging markets, and the emergence of innovative pain management treatments. Increasing research and clinical trials focused on pancreatitis treatment also contribute to market growth. The forecast period will see trends such as the employment of artificial intelligence in diagnostic imaging, adoption of minimally invasive surgical methods, the use of wearable devices for consistent health monitoring, the application of next-generation sequencing for genetic testing, incorporation of machine learning for disease progression charting, and the creation of intelligent diagnostic tools.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21146&type=smp
Which Primay Drivers Are Accelerating Growth in the Chronic Pancreatitis (CP) Market?
The escalating intake of alcoholic beverages is anticipated to fuel the expansion of the chronic pancreatitis industry. The term alcohol consumption typically implies the use of ethanol-inclusive drinks, typically for leisure, interpersonal, or cultural reasons. However, it can also lead to addiction or health hazards with overindulgence. Factors such as growing social approval, urban development, evolving lifestyles, and stress coping strategies, particularly among younger demographics, promote increased alcohol consumption. Chronic pancreatitis arises from alcohol consumption due to the encouraged inflammation and damage to the pancreas cells, leading to fibrosis, duct blocking, and long-term malfunction from harmful metabolic waste materials. For example, a report by Kirin Holdings Company Limited, a Japanese beer and beverage holding company, in December 2023 shows that the worldwide beer consumption in 2022 spiked by approximately 5.4 million kiloliters (equivalent to nearly 8.5 billion 633ml bottles) from 2021, attaining about 192.1 million kiloliters. This 2.9% surge was credited to the relaxation of COVID-19 consequences, equating to roughly 303.5 billion 633ml bottles. Hence, the rising alcohol consumption trajectories are bolstering the chronic pancreatitis industry’s growth.
Which Primary Segments of the Chronic Pancreatitis (CP) Market Are Driving Growth and Industry Transformations?
The chronic pancreatitis (cp)market covered in this report is segmented –
1) By Treatment: Analgesic; Artificial Digestive Enzyme; Protein Supplements; Steroids; Antibiotics; Other Treatments
2) By Diagnosis: Computed Tomography (CT) Scan; Magnetic Resonance Cholangiopancreatography; Ultrasound Sonography; Other Diagnosis
3) By Route Of Administration: Oral; Parenteral
4) By End User: Hospitals; Homecare; Other End Users
Subsegments:
1) By Analgesic: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs); Opioids
2) By Artificial Digestive Enzyme: Pancrelipase; Pancreatin
3) By Protein Supplements: Branched-Chain Amino Acids (BCAA); Whey Protein
4) By Steroids: Prednisone; Dexamethasone
5) By Antibiotics: Ciprofloxacin; Metronidazole
6) By Other Treatments: Endoscopic Treatment; Surgery
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21146&type=smp
Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Chronic Pancreatitis (CP) Market?# Market?
North America was the largest region in the chronic pancreatitis (CP) market in 2024. The regions covered in the chronic pancreatitis (cp) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Technological Trends Are Reshaping the Chronic Pancreatitis (CP) Industry Dynamics?
Leading entities in the chronic pancreatitis market are prioritizing the development of advanced technologies like enzyme replacement therapy to tackle exocrine pancreatic insufficiency (EPI) linked with chronic pancreatitis. This therapy consists of consuming pancreatic enzymes orally to aid the digestion of patients with deficient pancreatic function. To illustrate, First Wave BioPharma Inc, a US-based biopharmaceutical establishment engaged in clinical-stage drug development, disclosed in July 2023 the outcome of the Phase 2 SPAN clinical trial. This trial analyzed an improved enteric microgranule delivery formulation of adrulipase for treating EPI in patients suffering from cystic fibrosis (CF) and chronic pancreatitis. Adrulipase, an oral, non-systemic biologic capsule, is a recombinant lipase enzyme sourced from the Yarrowia lipolytica yeast, purposed to decompose fat molecules in EPI patients’ digestive tract for nutrient absorption.
View the full report here:
https://www.thebusinessresearchcompany.com/report/chronic-pancreatitis-cp-global-market-report
What Parameters Are Used to Define the Chronic Pancreatitis (CP) Market?
Chronic pancreatitis (CP) is a long-lasting, progressive inflammatory condition of the pancreas that causes permanent damage to its structure and function. The disease is marked by persistent inflammation, fibrosis (scarring), and the eventual deterioration of the pancreas’s ability to produce digestive enzymes and hormones such as insulin.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21146
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model